%0 Journal Article
%T Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
%A Adam J Savitz
%A David Hough
%A Haiyan Xu
%A Isaac Nuamah
%A Ludger Hargarter
%A Paulien Ravenstijn
%A Srihari Gopal
%J Archive of "Neuropsychiatric Disease and Treatment".
%D 2019
%R 10.2147/NDT.S189668
%X This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia
%K long-acting injectable
%K non-inferiority
%K randomized
%K relapse
%K tolerability
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391122/